quote:
The FDA rescinded its emergency use authorization (EUA) of hydroxychloroquine (HCQ) to treat COVID-19 patients, citing concerns about efficacy and risks associated with its use, and saying the drug no longer meets the criteria for an EUA, the agency said on Monday.
A brief paragraph at the bottom of the FDA's emergency use authorization page noted that the FDA has determined that based on continued review, the "statutory criteria" for an emergency use authorization are no longer met. The agency went on to say both hydroxychloroquine a related antimalarial drug, chloroquine (CQ), are "unlikely to be effective at treating COVID-19" for uses described in the EUA.
Moreover, the FDA now says the benefits of the drug "no longer outweigh the potential risks," citing the serious cardiac adverse events associated with the drug.
"This warrants revocation of the EUA for HCQ and CQ for the treatment of COVID-19," the agency said.
A letter from the agency to the Biomedical Advanced Research and Development Authority (BARDA) detailed the FDA's concerns, including that suggested dosing regimens are "unlikely to produce an antiviral effect," and said "decreased viral shedding" from treatment with these drugs, noted in some observational studies, "has not been consistently replicated."
While current FDA guidelines did not recommend use of the drugs outside of a randomized clinical trial, the FDA also pointed to recent data from a large clinical trial showing no "evidence of benefit" for mortality, effect on hospital length of stay, or need for mechanical ventilation among COVID-19 patients treated with hydroxychloroquine.